0601 GMT - Frencken Group's earnings are likely to recover further in 2024-2025, RHB Research analyst Alfie Yeo says in a research note as RHB raises the stock's target price to S$1.80 from S$1.45 with an unchanged buy rating. Its 2023 earnings outperformed RHB's estimates on order acceleration in its semiconductor segment, for which revenue trends should continue to improve as its key European customer continues to grow and expand into Asia, the analyst says. Also, the Singapore-listed technology solutions provider's positive revenue outlook will probably be supported by the medical segment, where topline is poised to increase on more robust customer orders, the analyst adds. Shares are 1.9% higher at S$1.63. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
March 01, 2024 01:01 ET (06:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments